For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Healing & Recovery

TB-500

Also known as: Thymosin Beta-4 fragment, TB4 fragment

Research use only · not FDA-approved

Synthetic fragment of Thymosin Beta-4 active site. Studied for actin sequestration, cell migration, and tissue repair.

Where to buy · live market data

Who's worth your money for TB-500

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (99) of 33 scored sellers

$5.90/mg

$58.99 · 10mg · 99.9% purity

2 COAs
Buy code MERIT · 10% off

Best value after code

$0.06/mg effective with 15% code

$0.07/mg

$0.65 · 10mg · 99.3% purity

4 COAs
Buy code MERIT · 15% off

Most tested

57 independent COAs on file

$3.72/mg

$37.20 · 10mg · 99.0% purity

Average price

$7.47/mg

Sellers

87

45-day trend

-7.5%

74 of 87 sellers have a current price· 29 stale hidden· 12 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch TB-500

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About TB-500

CAS

885340-08-9

Molecular formula

C38H68N10O14

Sequence

LKKTETQ

Typical dose range

2–5 mg subcutaneous or intramuscular, 1–2x per week; loading phase typically 4–6 weeks

Half-life

~1–2 hours (plasma; based on equine and in vitro studies)

Common research uses

soft tissue injury recovery (research only)wound healing studies

Safety notes

WADA-prohibited (S2 class). Not FDA-approved for human therapeutic use.

Reconstitution

Reconstitute with bacteriostatic water; stable refrigerated for ~4 weeks.

Independent evidence

COAs for TB-500

229 third-party tests across 42 vendors. Each card links to the full report.

All 229 COAs for TB-500 →
Measured purity 76.4%–100.0% across 155 COAs
Measured purity over time
✓ Vendor-published
99.75 %
Jul 2026
Kovera Labs

For

TB-500(TB-4)

by Ignite Peptides· batch IP-2607-898

COA on file
Aggregated · 3rd-party listing
99.58 %
Jul 2026
ILS Labs Strong

For

TB-500

by NG Peptide· batch TB10-08

✓ Vendor-published
99.89 %
Jul 2026
Janoshik Analytical Limited

For

TB-500

by EZ Peptides· batch EZP-TBF1006172026-06

COA on file
Aggregated · 3rd-party listing
99.82 %
Jun 2026
ILS Labs Strong

For

TB-500

by Ion Peptide· batch TB10-06092026

✓ Vendor-published
99.82 %
Jun 2026
ILS Laboratories

For

TB-500

by Ion Peptide· batch TB10-06092026

COA on file
✓ Vendor-published
98.32 %
Jun 2026
Janoshik Analytical Limited

For

TB-500 (TB-4)

by optimasupply.is· batch OS-2026-9422

COA on file
Aggregated · 3rd-party listing
99.94 %
May 2026
Janoshik Analytical Limited

For

TB-500

by EZ Peptides· batch EZP-TBF1005142026-05

Aggregated · 3rd-party listing
99.84 %
May 2026
Freedom Diagnostics Moderate

For

TB-500

by True Peptide· batch TB50--060-TPL

✓ Vendor-published
99.78 %
May 2026
TrustPointe Analytics Moderate

For

TB-500 (TB4)

by Peptide Partners· batch SPL-3956

COA on file
Aggregated · 3rd-party listing
99.52 %
May 2026
Janoshik Analytical Limited

For

TB-500

by Prime Peptides· batch 4142026TB

Aggregated · 3rd-party listing
99.19 %
May 2026
Chromate Moderate

For

TB-500 (Tβ4)

by Moglabs· batch TB002

Aggregated · 3rd-party listing
99.19 %
May 2026
Chromate Moderate

For

TB-500 (Tβ4)

by Arcane Peptides· batch TB002

✓ Vendor-published
99.19 %
May 2026
Chromate Moderate

For

TB-500 (TB4)

by Arcane Peptides· batch TB002

COA on file
✓ Vendor-published
99.19 %
May 2026
MogLabs.bio

For

TB-500 (TB4)

by Moglabs· batch TB002

COA on file
Aggregated · 3rd-party listing
99.70 %
May 2026
ILS Labs Strong

For

TB-500

by Ion Peptide· batch TB20-05072026

Aggregated · 3rd-party listing
98.89 %
May 2026
Janoshik Analytical Limited · HPLC

For

TB-500

by Prime Peptides· batch 4062026TB

Aggregated · 3rd-party listing
99.02 %
May 2026
Janoshik Analytical Limited

For

TB-500

by Verified Peptides· batch TB042609101

Aggregated · 3rd-party listing
99.95 %
May 2026
Janoshik Analytical Limited · HPLC

For

TB-500

by Verified Peptides· batch FTB06260510E

Aggregated · 3rd-party listing
99.95 %
May 2026
Janoshik Analytical Limited

For

TB-500

by Verified Peptides· batch FTB06260510E

Aggregated · 3rd-party listing
99.95 %
May 2026
Janoshik Analytical Limited

For

Frag(17-23) TB-500

by Verified Peptides· batch FTB0626Q510E

Aggregated · 3rd-party listing
99.20 %
May 2026
Freedom Diagnostics Moderate

For

TB-500

by Modern Research Peptides· batch BCEN27169

Aggregated · 3rd-party listing
99.87 %
May 2026
ILS Labs Strong

For

TB-500

by NG Peptide· batch TB20-5

Aggregated · 3rd-party listing
99.87 %
May 2026
ILS Labs Strong

For

TB-500

by NG Peptide· batch TB20-5

Aggregated · 3rd-party listing
99.81 %
May 2026
ILS Labs Strong

For

TB-500

by Ion Peptide· batch TB10-05042026

Research depth

15 citations indexed for TB-500

All research on TB-500 →

animal · 2026

Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study

Objectives This study aims to evaluate the effects of BPC-157, synthetic thymosin beta-4 (TB-500), and their combination on Achilles tendon healing using biomechanical, histopathological, histochemical, and immunohistochemical analyses in a rat model.

Study · 2026

Peptide Supplements and Their Therapeutic Applications in Sports Medicine

Background The peptide supplement market has experienced rapid growth due to marketing claims of enhanced performance and accelerated recovery from musculoskeletal injury.

review · 2026

Therapeutic peptides in gerontology: mechanisms and applications for healthy aging

Background Peptide therapeutics represent an emerging frontier in gerontological medicine, targeting fundamental hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline.

review · 2026

Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management

Purpose of review This narrative review summarizes the current evidence on regenerative peptides relevant to chronic pain management, including collagen peptides, body protection compound-157 (BPC-157), thymosin beta-4 (TB-4), thymosin beta-500 (TB-500), glycyl-L-histidyl-L-lysine copper (GHK-Cu), growth hormone-relate…

review · 2026

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians

Background Therapeutic peptides are short-chain amino acids that regulate cellular functions and facilitate biochemical processes. In recent years, there has been significant growth in the global market for therapeutic peptides and thus its popularity among patients.

review · 2026

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance

Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement.

Research use only — not for human consumption and not approved by the FDA. Nothing here is medical advice.